Otonomy (NASDAQ:OTIC) & Bio-Path (NASDAQ:BPTH) Financial Comparison
Otonomy (NASDAQ:OTIC) & Bio-Path (NASDAQ:BPTH) Financial Comparison
Otonomy (NASDAQ:OTIC – Get Rating) and Bio-Path (NASDAQ:BPTH – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.
Otonomy（NASDAQ：ODIQ-獲得評級）和生物路徑（NASDAQ：BPTH-獲得評級）都是小型股醫療公司，但哪個股票更好？我們將根據兩家企業的收益，股息，盈利能力，分析師建議，機構所有權，風險和估值來對比這兩家企業。
Analyst Recommendations
分析師推薦
This is a summary of recent ratings and target prices for Otonomy and Bio-Path, as reported by MarketBeat.com.
根據 MarketBeat.com 的報導，這是 Otonomy 和生物路徑的最近評分和目標價格的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Otonomy | 0 | 2 | 1 | 0 | 2.33 |
| Bio-Path | 0 | 0 | 1 | 0 | 3.00 |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| 音樂術 | 0 | 2 | 1 | 0 | 2.33 |
| 生物路徑 | 0 | 0 | 1 | 0 | 3.00 |
Otonomy currently has a consensus target price of $3.25, suggesting a potential upside of 3,182.83%. Bio-Path has a consensus target price of $9.00, suggesting a potential upside of 306.32%. Given Otonomy's higher possible upside, analysts plainly believe Otonomy is more favorable than Bio-Path.
Otonomy 目前的共識目標價為 3.25 美元，表明潛在的上行空間為 3,182.83％。生物路徑的共識目標價格為 9.00 美元，表明潛在的上行空間為 306.32％。鑑於 Otonomy 的可能較高的上升空間，分析師清楚地認為 Otonomy 比生物路徑更有利。
Volatility and Risk
波動性和風險
Valuation and Earnings
估值及收益
This table compares Otonomy and Bio-Path's revenue, earnings per share (EPS) and valuation.
此表格比較 Otonomy 和 Bio-Path 的收入、每股收益 (EPS) 和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Otonomy | $130,000.00 | 49.60 | -$51.18 million | ($0.77) | -0.13 |
| Bio-Path | N/A | N/A | -$10.44 million | ($1.97) | -1.12 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股盈利 | 市盈比率 | |
| 音樂術 | 130,000.00 | 49.60 | -5,118 萬美元 | (0.77 美元) | -0.13 |
| 生物路徑 | N/A | N/A | -1044 萬美元 | (一百九十七元) | -1.12 |
Bio-Path has lower revenue, but higher earnings than Otonomy. Bio-Path is trading at a lower price-to-earnings ratio than Otonomy, indicating that it is currently the more affordable of the two stocks.
生物路徑的收入較低，但收益高於 Otonomy。Bio-Path 以比 Otonomy 更低的價格盈利比進行交易，這表明它目前在兩隻股票中價格更便宜。
Insider & Institutional Ownership
內幕和機構所有權
41.2% of Otonomy shares are owned by institutional investors. Comparatively, 6.4% of Bio-Path shares are owned by institutional investors. 9.1% of Otonomy shares are owned by company insiders. Comparatively, 3.5% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
41.2％ 的 Otonomy 股票由機構投資者擁有。相比之下，Bio-Path 股份的 6.4％ 由機構投資者擁有。9.1％ 的 Otonomy 股份由公司內部人士擁有。相比之下，生物路徑股份的 3.5％ 由公司內部人士擁有。強大的機構擁有權表明，大型資金經理，捐贈基金和對沖基金認為公司有望實現長期增長。
Profitability
盈利
This table compares Otonomy and Bio-Path's net margins, return on equity and return on assets.
此表格比較 Otonomy 和 Bio-Path 的淨利潤率、權益回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Otonomy | N/A | -137.86% | -68.50% |
| Bio-Path | N/A | -67.16% | -62.17% |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| 音樂術 | N/A | -137.86% | -68.50% |
| 生物路徑 | N/A | -67.16% | -62.17% |
Summary
摘要
Otonomy beats Bio-Path on 7 of the 11 factors compared between the two stocks.
兩隻股票之間的 11 個因素中的 7 個因素中，Otonomy 擊敗了生物路徑。
About Otonomy
關於「音樂」
(Get Rating)
(取得評分)
Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.
Otonomy, Inc. 是一家生物製藥公司。從事神經病學治療藥物的開發。該公司的產品線包括奧替維克斯（地塞米松）梅尼爾氏病，奧替普利（環丙沙星懸浮液）急性中耳炎，帶管（AOMT），OTO-313（加基克列定）耳鳴，OTO-413（BDNF）隱性聽力損失，OTO-510（耳保護劑）防止耳朵重度損失（CIPHL），致聽力損失（CIHL）嚴重聽力損失（CIHL）。OTO-6XX它在奧蒂普里奧品牌下運作。該公司由傑伊 ·B· 利希特，杰弗裡·哈里斯，里克·弗里德曼和艾倫·瑞安於 2008 年 5 月 6 日成立，總部位於加利福尼亞州聖地亞哥。
About Bio-Path
關於生物路徑
(Get Rating)
(取得評分)
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
Bio-Path Holdings, Inc. 是一家生物技術公司，致力於開發急性髓細胞白血病（AML）和慢性髓細胞白血病（CML）療法。其產品管線包括普雷西伯森、BP1002 和 BP1003。該公司由彼得·尼爾森，道格拉斯 ·P· 莫里斯，加布里埃爾·洛佩斯-貝雷斯坦和安娜·塔里蘆澤於 2007 年 5 月 10 日成立，總部設在德克薩斯州貝萊爾。
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Otonomy 日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件時事通訊接收 Otonomy 和相關公司的最新新聞和分析師評級的簡要每日摘要。